Brief: Gossamer Bio Announces Seralutinib Meets Primary Endpoint In Phase 2 Torrey Study In PAH

Gossamer Bio

06/12/2022 12:54

Dec 6 (Reuters) - Gossamer Bio Inc  GOSS.O :
    * GOSSAMER BIO ANNOUNCES SERALUTINIB MEETS PRIMARY ENDPOINT
IN
PHASE 2 TORREY STUDY IN PAH
    * GOSSAMER BIO INC - PRIMARY ENDPOINT, CHANGE IN PVR AT WEEK
24,
MET WITH P-VALUE OF 0.0310
    * GOSSAMER BIO INC- STATISTICALLY SIGNIFICANT IMPROVEMENTS
OBSERVED IN NT-PROBNP AND ECHO MEASURES OF CARDIAC STRUCTURE AND
FUNCTION
    * GOSSAMER BIO INC - SECONDARY ENDPOINT, CHANGE IN 6MWD,
NUMERICALLY FAVORED SERALUTINIB
    * GOSSAMER BIO INC- SERALUTINIB WAS WELL TOLERATED AND
AVOIDED
HIGH FREQUENCY ADVERSE EVENTS OBSERVED IN IMATINIB IMPRES STUDY
    * GOSSAMER BIO INC - CONSISTENTLY POSITIVE RESULTS SEEN
ACROSS
PRE-SPECIFIED SUB-GROUPS

Source text for Eikon:  ID:nBwYH3Gha 
Further company coverage:  GOSS.O